retatrutide clinical trial south korea Lilly's 'triple G' agonist triumphs in Phase III trial, but AEs unnerve analysts Lilly's triple agonist, retatrutide, delivered

Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring

The single-dose segment held the largest share, owing primarily to its ease of administration and convenience for patients

What Results Can You Expect

Only 11.2% of participants discontinued treatment due to side effects, meaning nearly 9 out of 10 people tolerated Retatrutide successfully through the entire study period

Seek urgent medical advice if you experience difficulty swallowing, vomiting blood, black tarry stools, or severe chest pain call 999 immediately for severe chest pain with breathlessness or pain radiating to the arm or jaw

GLP-1 medications may be most appropriate for patients new to weight loss medications seeking proven, well-studied options